Talk Abstract Parallel track
Advancing Risk Stratification in MASLD and MASH: Biomarkers, Machine Learning, and Noninvasive Tools
Sun, Nov 8, 2026 · 8:00–9:30 AM MST Convention Center: Bluebird Ballroom 1A, Colorado Convention Center
About this session
This session will highlight emerging approaches to identifying patients with steatotic liver disease who are at greatest risk for advanced liver disease and adverse outcomes. Presentations will explore the role of lipid biomarkers, body phenotype, alcohol exposure assessment, noninvasive diagnostic criteria, and adaptive machine-learning strategies. Together, these studies underscore the evolving role of precision risk stratification in MASLD, MASH cirrhosis, and clinical trial prescreening.
Speakers
-
CIC bioGUNE
Speaker
